United States · Markets & Finance · The Motley Fool

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

Published by The Motley Fool · United States 8 h ago

Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.

Read the full article on The Motley Fool Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

Business Insider

I moved my family from Australia to New York City 12 years ago. It's led to some very expensive regrets.

China passenger vehicle retail market slumps 24% in September

Trump says he’s evaluating whether the U.S. should join Saudi Arabia’s fight against Iran-backed Houthi rebels in Yemen after fresh attacks on Riyadh

CFTC Draws the Line Between Prediction Markets and Gambling in New Rules

Petra Power looks to modernize energy for data centers and defense vehicles

Kasai, Klarity and 8 other baby names surging in America